Healthcare · Biotechnology · Synthos Deep Dive · 2026-07-03
| Verdict | Watch — systematic Synthos tier |
| Price (2026-07-02) | $312.78 · market cap ~$41.8B |
| Synthos scores (0–10) | Downside Risk 5 · Growth Quality 8 · Exponential Potential 7 |
| Synthos fair value (base case) | ~$330 → +5% · full range $185 (bear) – $470 (bull) |
| Street consensus | $451 (high $530 / low $370; 39 Buy · 12 Hold · 1 Sell) — context, not our anchor |
| Valuation | 72× trailing EPS · 42× FY26E · 30× FY27E · 24× FY28E · 16× FY30E · EV/S 9.6× · EV/EBITDA 45× |
| Exponential Potential | 7/10 · High — ~26% forward revenue CAGR accelerating (rev +65% FY25, Q1'26 +96% YoY); $42B cap leaves room to run |
| Technicals | Mixed — $313, −36% off 52-wk high, above 50-DMA but below 200-DMA, RSI 69, −2.9% 12-mo (SPY +21%, QQQ +30%) |
| Conviction | Moderate — 0 expert voices in the Synthos KB; call rests on fundamentals + quant |
| Position sizing | Satellite, ~1–3% — a growth kicker, not a core holding |
| Next catalyst | 2026-07-30 Q2'26 earnings (Street EPS $2.04, revenue ~$1.32B) |
| Single biggest risk | Franchise concentration — the whole growth curve leans on the TTR-amyloidosis (vutrisiran/AMVUTTRA) ramp |
One-line thesis. Alnylam is the pure-play leader in RNA interference (RNAi) medicines that just crossed the inflection every platform biotech chases — FY25 revenue +65% to $3.71B and its first full-year profit — driven by the transthyretin-amyloidosis franchise; the business quality and acceleration are real, but the stock trades at 42× forward earnings with no expert-panel coverage, so we own it as a satellite growth position, not a core one.
Alnylam makes a new kind of medicine. Instead of a normal pill that blocks a protein after your body makes it, its drugs (called RNAi) quietly switch off the genetic instruction so the harmful protein is never made in the first place. Its big winner treats a disease called ATTR amyloidosis, where a faulty protein builds up and damages the heart and nerves.
For years Alnylam spent far more than it earned — normal for a company inventing a whole new drug technology. That just changed: in 2025 sales jumped 65% and the company turned its first-ever annual profit. The balance sheet is strong (more cash than debt), and the stock barely moves with the market.
The catch: the stock is expensive and has actually fallen about 36% from its high, badly lagging the market over the past year. You are paying a rich price for fast growth, and no outside expert in our research library covers this name — so our conviction is moderate. Our verdict is Buy as a smaller "satellite" position — a growth kicker you size modestly, not a cornerstone.
Here's what our three scores mean in everyday terms:
The one big worry: almost all the growth leans on the ATTR-amyloidosis franchise. If that ramp slows — competition, pricing, or a trial setback — the rich valuation has a long way to fall.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Above 70 (red band) = overbought, below 30 (green band) = oversold. Currently 64.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Solid = ALNY · dashed = S&P 500 · dotted = XLV (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
Alnylam Pharmaceuticals (Nasdaq: ALNY), founded 2002, Cambridge MA, is the pure-play pioneer of RNA-interference (RNAi) therapeutics — a class of drugs (small interfering RNAs, "siRNAs") that silence a target gene so the disease-causing protein is never produced. It is the category leader, having brought the first-ever approved RNAi medicines to market. Fiscal year ends December 31.
The commercial engine today is the transthyretin-amyloidosis (ATTR) franchise — patisiran (ONPATTRO) and, critically, the newer vutrisiran (AMVUTTRA), whose expansion into ATTR cardiomyopathy is the single biggest driver of the recent revenue explosion. Around it sit rare-disease products GIVLAARI (acute hepatic porphyria) and OXLUMO (primary hyperoxaluria), plus a broad partnered pipeline: inclisiran (cholesterol, partnered with Novartis, sold as Leqvio), fitusiran (hemophilia), zilebesiran (hypertension, with Roche), and earlier CNS/ocular programs with Regeneron. Major alliances: Regeneron, Novartis, Roche, Sanofi.
Revenue mix (FMP segmentation — note it is partial):
The strategic story is a platform reaching scale: one validated RNAi engine (GalNAc-conjugated siRNA, largely liver-targeted) producing repeatable, durable, infrequently-dosed medicines — with the TTR cardiomyopathy opportunity as the value inflection and hypertension (zilebesiran) as the next large-market shot.
There is no expert coverage of ALNY in the Synthos knowledge base. total_claims = 0; there are zero net-bullish (or bearish) voices to cite. We will not manufacture conviction we do not have: there are no claim_id values to reconcile, and this deep dive is therefore explicitly fundamentals- and quant-driven, not conviction-driven.
What that means for the reader:
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 5 · Moderate | Net cash (−0.47× net-debt/EBITDA) and beta 0.27 make it financially and price-wise sturdy; offsetting that, 72× trailing / 42× forward leaves no error margin, it is already −36% off its high, and revenue leans heavily on one franchise. |
| Growth Quality | 8 · High | ~26% forward revenue CAGR, first profitable year (FY25), 82% gross margin, ROIC ~20%, ROE strong, and a genuinely hard-to-replicate RNAi platform. Not yet a long profit track record — hence 8 not 9. |
| Exponential Potential | 7 · High | Growth is accelerating (rev +65% FY25, Q1'26 +96% YoY), and at $42B the cap is small enough to multiply against an expanding RNAi TAM (TTR cardiomyopathy + hypertension optionality). A far bigger name with the same numbers would score lower. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | TTR cardiomyopathy ramp beats and zilebesiran/pipeline optionality gains credibility. FY27E EPS beats to ~$12.3 (vs $10.52 cons); a high-growth platform holds a premium ~38×. | ~$470 (+50%) |
| Base (our anchor) | Estimates roughly hit — FY27E EPS $10.52; a durable ~25% grower that just turned profitable earns a ~31× forward multiple. | ~$330 (+5%) |
| Bear | Competitive pressure in TTR (tafamidis, Ionis, others), pricing erosion, or a pipeline setback; the market de-rates a still-rich name. FY27E EPS misses to ~$8.4; multiple compresses to ~22×. | ~$185 (−41%) |
Synthos fair value = the base case, ~$330 (+5%), with the full $185–$470 span as the honest range. Our base sits well below the Street's $451 consensus: the sell-side is pricing outer-year franchise dominance we are not willing to underwrite without expert corroboration, and at 42× forward earnings the reward-to-risk is balanced, not lopsided. This is a tracked call — the Forecaster Scorecard grades it once it matures.
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). ALNY leans toward the exponential end — a platform at its profitability inflection with the acceleration still ahead of the deceleration:
Exponential Potential: High (7/10). Own it for accelerating, platform-driven growth with real optionality — sized as a tactical position because the valuation is full and there is no expert-panel ballast.
There is no way to call ALNY cheap on trailing numbers (72× EPS, 9.7× sales, 45× EV/EBITDA, 39× book). The growth defense is that EPS compounds faster than the multiple: on live consensus the forward P/E steps down 42× (FY26E) → 30× (FY27E) → 24× (FY28E) → 16× (FY30E) — the multiple compresses hard even at a flat price if estimates hit. A reverse read: today's ~$313 already embeds a mid-20s% multi-year revenue CAGR and continued margin expansion, so the setup is priced for execution with modest cushion. Street targets (context): consensus $451, high $530, low $370 — the sell-side is markedly more bullish than our $330 base, largely on outer-year franchise assumptions we discount absent expert corroboration. FMP letter rating "B" flags the tension cleanly: strong return-on-capital scores (ROE/ROA 5/5) against maximally stretched valuation scores (P/E, P/B, D/E all 1/5). Not a value buy; a quality-growth-at-a-full-price buy, which is exactly why it is a satellite.
Alnylam's moat is platform + IP + first-mover scale in RNAi: a validated GalNAc-siRNA delivery engine, deep foundational intellectual property in RNAi, durable infrequent-dosing product profiles, and the manufacturing/clinical know-how of the category pioneer. The switching-cost and data advantages compound as the platform produces repeat wins (patisiran → vutrisiran → inclisiran → zilebesiran). The threats are real: in TTR amyloidosis it competes with tafamidis (Pfizer) and antisense rivals (Ionis/Akcea, and BridgeBio's acoramidis), and next-gen gene-editing approaches (e.g. Intellia) could one day pressure the chronic-dosing model.
Peer set (FMP-supplied, market cap): Regeneron $67B, argenx $58B, Cigna $76B, Cencora $58B, Becton Dickinson $57B, Cardinal Health $56B, Edwards Lifesciences $54B, IDEXX $44B, Veeva $31B, Zoetis $31B. Note the FMP peer list is a broad healthcare basket, not RNAi comps — the truer competitive frame is Ionis, BridgeBio, Intellia, and large-pharma TTR incumbents (Pfizer). Among the listed peers, ALNY carries one of the highest growth rates and the richest sales multiple — justified only if the ramp persists.
mgmt claims ingested). Treat company guidance from the earnings release as directional; our numbers key off FMP analyst consensus, labeled as estimates.Thesis tripwires (what would change the call): two consecutive quarters of TTR-franchise growth deceleration; a competitive efficacy/label setback in ATTR; FCF slipping back negative; or a net-margin reversal as R&D re-accelerates without matching revenue.
Buy — Tactical. ALNY is a genuinely high-quality, accelerating platform that just cleared the profitability inflection every platform biotech aims for — FY25 revenue +65% to $3.71B, first annual profit ($314M net, $2.33 diluted EPS), positive FCF ($465M), and a net-cash balance sheet with beta 0.27. Growth Quality (8) and Exponential Potential (7) are both high, and the acceleration is live through Q1'26 (+96% YoY). But two honest checks keep it out of the core: (1) the valuation is full (42× forward, base-case FV only ~+5% to $330, below the Street's $451), and (2) there is zero expert coverage in the Synthos KB, so the call is fundamentals/quant only. The 12-month underperformance (−3% vs SPY +21%, QQQ +30%) is the tension — the business accelerated while the stock de-rated.
claim_id values are cited because none exist; the verdict is fundamentals- and quant-driven. Fabricated conviction is structurally impossible (claim-ID reconciliation).